FIELD: medicine.
SUBSTANCE: group of inventions refers to ophthalmology and oncology, and is intended for the treatment of eye and oncological diseases. For the treatment of eye diseases or cancer, a nanoparticle is used, including a solid core containing a non-crosslinked albumin matrix and monoclonal antibodies distributed throughout the volume of the albumin matrix, and when the said solid core is coated, it is coated with a non-ionic polymer. In other embodiments, the said nanoparticle and pharmaceutical compositions are provided containing a group of the said nanoparticles and an excipient, pharmaceutically acceptable carrier or excipient.
EFFECT: use of the group of inventions provides effective treatment of cancer and eye diseases achieved due to the controlled delivery of monoclonal antibodies while maintaining their integrity and activity.
25 cl, 22 dwg, 7 tbl, 14 ex
| Title | Year | Author | Number |
|---|---|---|---|
| NANOPARTICLE (VERSIONS), COMPOSITION CONTAINING SAID NANOPARTICLE, FOOD PRODUCT INCLUDING SAID COMPOSITION AND METHOD OF PRODUCING SAID NANOPARTICLE (VERSIONS) | 2011 |
|
RU2552957C2 |
| APPLICATION OF ANTICANCER TRANSCRIPT MODIFYING AGENTS AND CHEMOTHERAPY OR RADIOTHERAPY | 2005 |
|
RU2389484C2 |
| NANOPARTICLE (VERSIONS), METHOD FOR NANOPARTICLE OBTAINING (VERSIONS), COMPOSITION AND FOOD PRODUCT | 2011 |
|
RU2575745C2 |
| METHOD OF INHIBITING ANGIOGENESIS BY EGFL8 ANTAGONISTS | 2009 |
|
RU2486200C2 |
| ANTIBODIES AGAINST CCR7 RECEPTOR FOR CANCER TREATMENT | 2006 |
|
RU2404808C2 |
| PEG-YLATED NANOPARTICLES | 2005 |
|
RU2400215C2 |
| USE OF ADIPOSE TISSUE-DERIVED STROMAL STEM CELLS IN TREATING FISTULA | 2011 |
|
RU2608641C2 |
| COMPOSITIONS WITH PACLITAXEL, ALBUMIN AND BINDING AGENT AND METHODS FOR THEIR USE AND PREPARATION | 2017 |
|
RU2756892C2 |
| USE OF ADIPOSE-DERIVED STROMAL STEM CELLS FOR TREATING FISTULAS | 2016 |
|
RU2744977C2 |
| COMBINATIONS AND METHODS FOR ADMINISTRATION OF THERAPEUTIC AGENTS AND COMBINATION THERAPY | 2013 |
|
RU2673805C2 |
